MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Zai Lab Limited Operating Cash Flow 2011-2026 | ZLAB
Annual Operating Cash Flow Zai Lab Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -151 M | -215 M | -198 M | -368 M | -549 M | -216 M | -191 M | -97.5 M | -32.4 M | -32.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -32.2 M | -549 M | -205 M |
Quarterly Operating Cash Flow Zai Lab Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -61.7 M | - | - | - | -90.1 M | - | - | - | -69.3 M | - | -258 M | -132 M | -87.1 M | - | -396 M | -235 M | -170 M | - | -172 M | -92.3 M | -39.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -39.8 M | -396 M | -150 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
-8.24 M | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B | France |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-10.4 M | $ 0.8 | -3.59 % | $ 36.6 M |  Israel |
 |
Athira Pharma
ATHA
|
-45.7 M | - | - | $ 269 M | USA |
 |
Exelixis
EXEL
|
884 M | $ 46.21 | -5.11 % | $ 12.5 B | USA |
 |
Fortress Biotech
FBIO
|
-65.8 M | $ 2.4 | -5.88 % | $ 67 M | USA |
|
Forte Biosciences
FBRX
|
-50.9 M | $ 26.17 | -1.32 % | $ 339 M | USA |
 |
Heron Therapeutics
HRTX
|
-27.6 M | $ 1.24 | -5.34 % | $ 207 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
-269 M | $ 76.02 | -1.08 % | $ 12.2 B | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 93.02 | -2.35 % | $ 27.2 B | Germany |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
97 M | $ 210.33 | -9.55 % | $ 3.85 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
158 M | $ 22.57 | 5.05 % | $ 3.74 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
55.8 M | $ 102.93 | -6.5 % | $ 5.17 B | USA |
 |
MannKind Corporation
MNKD
|
18.3 M | $ 3.55 | -0.28 % | $ 1.09 B | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Esperion Therapeutics
ESPR
|
-13.1 M | $ 3.14 | -0.32 % | $ 653 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.95 M | $ 3.54 | 5.67 % | $ 5.83 M | Israel |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Genprex
GNPX
|
-15.3 M | $ 0.87 | -2.84 % | $ 811 K | USA |
 |
Matinas BioPharma Holdings
MTNB
|
-7.01 M | $ 0.65 | -5.15 % | $ 3.56 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
-38.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-5.62 M | $ 20.66 | -14.52 % | $ 2.63 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Genmab A/S
GMAB
|
1.33 B | $ 27.06 | -2.98 % | $ 16.7 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
|
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
-55.2 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-29.1 M | - | 17.91 % | $ 11.1 M | USA |